Expresion of DD3^PCA3 (Differential Display Code 3) mRNA in tissue of patients with prostate cancer and benign prostatic hyperplasia

Czech version

Authors: Jiří Klečka ¹; Milan Hora ¹; Luboš Holubec ³; Martin Pešta ²; Ondřej Topolčan ²; Viktor Eret ¹; Magdalena Chottová-Dvořáková ⁴; Marko Babjuk ⁵; Květoslav Novák ⁵; Josef Stolz ⁵
Authors‘ workplace: Urologická klinika LF UK a FN, Plzeň ¹; Centrální radioizotopová laboratoř LF UK, Plzeň ²; Radioterapeutické oddělení FN a LF UK Plzeň ³; Ústav fyziologie LF UK, Plzeň ⁴; Urologická klinika 1. LF UK a VFN, Praha ⁵
Published in: Ces Urol 2010; 14(1): 39-47
Category: Original article

Overview

Aim:
Early diagnosis of prostate cancer (PCa) in organ confined stage with following radical treatment are only potential currative approach in PCa. Prostatic specific antigen (PSA) is very helpful in early diagnosis, but the main disadvantage is a low positive predictive value, which results in a high number of uselless biopsies. For that reason we need new tests with better parameters. One promising is DD3^PCA3, which is a prostate-specific non-coding mRNA that is highly over-expressed in prostate tumor cells. The aim of study was to evaluate diagnostic potential of DD3^PCA3 for PCa diagnostic.

Material and methods:
We examined altogether 186 patients. In group of patients with suspicion of PCa we collected one tissue specimen core for PCA3 espression in tissue. According to the histologically verification 100 patients with benign prostatic hyperplasia (BPH), and 86 patients with prostate cancer (12 patients from them had prostatic intraepithelial neoplasia (PIN)). Total RNA were isolated, PCA3 and PSA expression quantified using Q RT PCR method. The PCA3/PSA m RNA ratio distribution was determined for both subject groups.

Results:
It was found that levels of mRNA expressions of DD3^PCA3 (Ct) were significantly higher (p < 0.045) in patients with prostate cancer than in patients with benign prostatic hyperplasia. We found no statistically diferencies in patients with prostate cancer in levels of mRNA expressions of DD3^PCA3 (Ct) between patients with organe confined and advanced (metastatic) dissease and according to Gleason score.

Conclusion:
The specificity of mRNA DD3^PCA3 detection seems to be perspective for early differential diagnosis between patients with BPH and patients with prostate cancer.

Key words:
prostate cancer (CaP), benign prostatic hyperplasia (BPH), DD3^PCA3, mRNA, RT PCR

Sources

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49(1): 8–31.

2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106–130.

3. SVOD (System for Visualization of Oncological Dates version 6); http: //www.svod. cz/analyse.php?modul=incmor#

4. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate–specific antigen in men with an initiai PSA level of 3.0 ng/ml or lower. JAMA 294: 66–70, 2005.

5. Stamey TA, Caldwell M, McNeal JE, et al. The prostate specitic antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172: 1297–1301.

6. Karazanashivili G, Abrahamsson PA. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol 2003; 169: 445–457.

7. Punglia RS, D’Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 46: 307–310.

8. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975–5979.

9. Hessels D, Klein Gunnewiek JM, et al: DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8–16.

10. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695–2698.

11. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; 64: 311–316.

12. Tinzl M, Marberger M, Horvath S, et al. DD3/PCA3 RNA analysis in urine a new perspective for detecting prostate cancer. Eur Urol 2004; 46: 182–187.

13. Groskopf J, Auhin SMJ, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089–1095.

14. Marangoni K, Neves AF, Cardoso AM, Santos WK, Faria PC, Goulart LR. The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Cancer Detect Prev 2006; 30: 7–13.

15. Huggett J, Dheda K, Bustin S, Zumla A. Real time RT-PCR normalisation; strategics and considerations. Genes Immun 2005; 6: 279–284.

16. Polascik TJ, Oesterling JE, Partin AW, et al. Prostate specific antigen: a decade of discovery what we have learned and where we are gomg. J Urol 1999; 162(2): 293–306.

17. Thompson IM, Carroll P, Coley C, et al. Prostate-specific antigen (PSA) best pracrice policy. Oncology 2000; 14: 267–286.

18. Vollmer RT. Predictive probability of serum prostate specific antigen for prostate cancer: an approach using Bayes rule. Am J Clin Pathol 2006; 125: 336–342.

19. Roehl KA, Antenor JA and Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002; 167: 2435–2439.

20. Clements JA, Rhode P, Allen V, Hyland VJ, Samaratunga ML. Tillev WD, et al. Molecular detection of prostate cells in ejaculate and urethral washings of men with suspected prostate cancer. J Urol 1999; 161: 1337–1342.

21. Muller M, Goessl C, Krause H, Miller K. Molecular diagnostics in urologie oncology. Detection of nucleic acids in urine samples. Urologe A 2003; 42: 660–668.

22. Goessl C, Muller M, Heicappell R, Krause H, Straub B. Schrader M, et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001; 58: 335–338.

23. Cairns P, Esteller M, Hermann JG, Schoenberg M, Jeronimo C. Sanchez-Cespedes M, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001; 7: 2727–2730.

24. Ylikoski A, Karp M, Lilja H, Lovgren T. Dual-label detection of amplified products in quantitative RT-PCR assay using lanthanide-labeled probes. Biotechniques 2001; 30(4): 832–836.

25. Meid FH, Gygi CM, Leisingcr HJ, Bosman FT, Benhattar J. The use of telomerase activity for the detection of prostatic cancer cel1s after prostatic massage. J Urol 2001; 165: 1802–1805.

26. Fradet Y. Saad F, Aprikian A, Dessureault J. Elhilali M. Trudel C, Masse B, Piche L, Chypre C. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2006; 21: 560–564.